Shanghai Bao Pharmaceuticals Co., Ltd.

We are a biotechnology company with two approved products and a diverse clinical pipeline, leveraging synthetic biology technology to develop and deliver recombinant biologic drugs in China, targeting conditions with limited treatment options and complex manufacturing challenges. From our inception, we have strategically focused on creating biologic drugs that elevate treatment standards by replacing biochemically extracted products derived from animal organs, blood or urine, or otherwise upgrading the current treatments. We have established proprietary technology platforms, supported by our chassis cell engineering technology, combining our drug design and bioprocessing capabilities. Our technology platforms enable us to achieve a competitive position in developing drug candidates across four strategic therapeutic areas with a combined clinically addressable market size of approximately RMB50 billion in total by 2033 according to Frost & Sullivan: (i) large-volume subcutaneous (SC) drug delivery, (ii) antibody-mediated autoimmune conditions, (iii) drugs in assisted reproduction and (iv) recombinant biologic products as transformative alternative to traditional biochemical production.